im US Handel bei 72 USD
Morgen Handelsaussetzung:
The trading of Abivax’s Ordinary Shares on Euronext is expected to be suspended on July 24, 2025 until the opening of trading of Abivax’s ADSs on the Nasdaq Global Market at approximately 3:30 pm (Paris time) / 9:30 a.m. (New York time) on July 24, 2025, prior to which Abivax is expected to publish the allocation of share capital to be effective following settlement and delivery of the securities sold in the Offering.
- Abivax SA#2X1(A14UQC)
56,10 -3,2%Abivax SA
56,10 €
18:11:44-1,85 €
-3,19 %Hoch: 59,70 €
Tief: 54,15 €
- Symbol:
- 2X1
- WKN:
- A14UQC
- ISIN:
- FR0012333284
Abivax Announces Launch of Public Offering
PARIS, France, July 23, 2025 - 10:15 p.m. (CEST) - Abivax SA (Euronext Paris: <FR0012333284> - ABVX) ("Abivax" or the "
Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural
regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today
the launch of an approximately USD400 million underwritten public offering (representing approximately EUR340 million)
consisting of a public offering of its American Depositary Shares ("ADSs"), each representing one ordinary share, EUR0.01
nominal value per share (each an "Ordinary Share"), of the Company in the United States (the "Offering"). In connection
with the Offering, the Company intends to grant the underwriters for the Offering a 30-day option to purchase
additional ADSs, in an amount of up to 15% of the total number of ADSs proposed to be sold in the Offering, on the same
terms and conditions.